platoseedplatoseed
Computational antibody design
Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.
Macromoltek provides AI-driven computational antibody design services to accelerate antibody discovery and engineering for biotech and pharma partners. Their platform uses AI, computational modeling, and structure prediction to improve specificity, affinity, and developability while reducing development time.
The company offers AI-driven antibody discovery and computational structure modeling to identify and optimize antibodies with high specificity and affinity. Their platform applies proprietary algorithms for rapid candidate identification, epitope mapping, developability assessments, and structural optimization, enabling partnerships that range from early research to clinical development and custom antibody engineering with flexible engagement models.
Who it’s for: Biotech and pharmaceutical companies engaged in antibody discovery and development seeking accelerated timelines and optimized antibody candidates.
company mentions investors/awards of founders and leadership; ongoing client partnerships implied
Monica Berrondo, Ph.D., is an entrepreneur, scientist, and software engineer. Her expertise lies in antibody structure-prediction and analysis, protein functional analysis, protein mutational analysis, and computational approaches to complex scientific problems.
We create activating antibodies to treat diseases others can’t.
AI-designed Affinity Reagents
